April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Design Considerations and Performance of a Next-Generation Encapsulated Cell Technology Intraocular Implant Delivering VEGF-Antagonist
Author Affiliations & Notes
  • Konrad Kauper
    Neurotech Pharmaceuticals, Cumberland, RI
  • Michael Rivera
    Neurotech Pharmaceuticals, Cumberland, RI
  • John Mills
    Neurotech Pharmaceuticals, Cumberland, RI
  • Alline Lelis
    Neurotech Pharmaceuticals, Cumberland, RI
  • Megan Billings
    Neurotech Pharmaceuticals, Cumberland, RI
  • Cahil McGovern
    Neurotech Pharmaceuticals, Cumberland, RI
  • Arne Nystuen
    Neurotech Pharmaceuticals, Cumberland, RI
  • Sandy Sherman
    Neurotech Pharmaceuticals, Cumberland, RI
  • Pam Heatherton
    Neurotech Pharmaceuticals, Cumberland, RI
  • Rhett Schiffman
    Neurotech Pharmaceuticals, Cumberland, RI
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 441. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Konrad Kauper, Michael Rivera, John Mills, Alline Lelis, Megan Billings, Cahil McGovern, Arne Nystuen, Sandy Sherman, Pam Heatherton, Rhett Schiffman; Design Considerations and Performance of a Next-Generation Encapsulated Cell Technology Intraocular Implant Delivering VEGF-Antagonist. Invest. Ophthalmol. Vis. Sci. 2014;55(13):441.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Early generation ECT products delivering VEGF-antagonist (VEGF- α) for over a year have demonstrated clinically meaningful improvements in BCVA and reductions in macular thickening in patients with active neovascular AMD; higher dose levels are expected to achieve efficacy comparable or greater than standard-of-care treatments. A new ECT device, NT-503-3, incorporating multiple, optimized cell encapsulation chambers into a single cartridge implant was designed to substantially increase the dose of VEGF-α by increasing the total number of encapsulated cells, and by improving cell viability and protein expression efficiency. This design also supports combination therapy from a single device, by allowing discrete encapsulations of different therapeutic cell lines in a single intraocular implant product.

Methods: The performance of NT-503-3 was evaluated following encapsulation of a human RPE cell line transfected to produce VEGF-α. Dose levels of VEGF-α were characterized by ELISA; binding efficiency and affinity were quantified by a VEGF-inhibition and Bioacore assay, respectively. GLP toxicology studies, which include clinical examination, ERG, ocular histopathology, and detection of serum antibodies to VEGF-α and the encapsulated cell line, are ongoing.

Results: A single NT-503-3 implant increased VEGF-α dose 5-fold compared to the previous ECT product (NT-503-2) which had demonstrated clinical efficacy in wet-AMD patients when implanted with two devices. VEGF-α produced by NT-503-3 results in high binding affinity to VEGF with a Kd of 0.7 pM and inhibits VEGF with an IC50 of 20-30 pM. Intraocular implants in rabbits and mini-pigs demonstrate that the NT-503-3 product is safe and well tolerated.

Conclusions: Clinically relevant VEGF-α expression and an excellent toxicology profile has been achieved with the novel NT-503-3 design. A single, intraocular NT-503-3 implant is anticipated to provide equivalent or improved efficacy compared to standard-of-care therapy while eliminating the burden of frequent injections in patients with active neovascular AMD. Furthermore, the new ECT cartridge design also supports ongoing combination therapy development.

Keywords: 748 vascular endothelial growth factor • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 701 retinal pigment epithelium  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×